Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)192.98K
Market Cap
$37.13M
Enterprise Value$9.15
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$59.08K
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Aug 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,758,872
10 Day Avg. Volume177,143
30 Day Avg. Volume192,978
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI PlatformZetaOmics institutionalizes Lantern’s AI/ML capabilities into an autonomous computational‑biology module focused on multi‑omic analysis and rare/pediatric cancers. As a durable tech asset, it can drive recurring partnerships, subscription revenue, and differentiation versus peers, increasing pipeline efficiency and deal optionality over multiple development cycles.
Low LeverageVery low debt gives the company financial flexibility during lengthy clinical timelines and reduces interest burden risk. For a development-stage biotech, low leverage preserves optionality to structure collaborations or equity financings without immediate solvency stress, supporting sustained R&D investment capacity.
Mid‑stage Clinical ProgressAdvancing LP‑300 through a Phase 2 program and transparent regulatory communications (investor presentation/Type C interactions) represent durable de‑risking steps. Measurable clinical progress increases the asset’s partnering and licensing attractiveness and materially improves the pathway to pivotal studies and eventual commercialization options.
Bears Say
No Commercial RevenueWith no product revenues, Lantern’s value realization depends entirely on R&D success, external financings, or partnership monetization. This structural absence of operational cash flow lengthens the path to self‑sufficiency and heightens binary risk tied to clinical outcomes and partner interest.
Heavy Cash BurnPersistent negative operating and free cash flow means the company cannot internally fund development. This creates ongoing dependency on external capital, raising dilution and runway uncertainty risks, and limits strategic optionality if market conditions or financing windows tighten over the medium term.
Small Scale And Balance InstabilityA very small operating base constrains in‑house development bandwidth and increases reliance on partners or contractors. Combined with uneven equity balances across years, this suggests structural sensitivity to financing events and potential governance or execution volatility as the company scales clinical programs and commercial plans.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $37.13M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 25 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 15, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 12,758,872 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.06%
12-Months-Change
Fundamentals
Return on Equity
-0.97%
Trailing 12-Months
Asset Growth
-65.76%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
LTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
1.12% Insiders
3.30% Mutual Funds
9.54% Other Institutional Investors
82.54% Public Companies and
Individual Investors